Compare Vaxcyte Inc. Common Stock (PCVX) vs Planet Labs (PL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vaxcyte Inc. Common Stock vs Planet Labs — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while Planet Labs trades at $13.82 (market cap $5.52B). The key difference: Vaxcyte Inc. Common Stock is the larger of the two by market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Planet Labs nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and Planet Labs for 6 Days on average.
| PCVX | PL | |
|---|---|---|
Market Cap | $10.51B | $5.52B |
Volume | 2,644,694 | 10,123,547 |
Sector | Health | Industrials |
52-Week High | $73.82 | $51.40 |
52-Week Low | $40.32 | $11.16 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $9.14B | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Planet Labs (PL) trades at $15.16, down 5.01% on the day, reflecting ongoing bearish technical pressure despite recent satellite launches and government contract wins. The company shows revenue growth potential with $378 million projected for 2026, but faces significant profitability challenges with a -95.13% net income margin and negative ROE of -71.97%. Analyst sentiment remains positive with 13 buy ratings and a $32.50 consensus price target, though technical indicators signal bearish momentum.
The stock presents a high-risk opportunity with substantial upside potential if execution improves, but current financial performance and bearish technicals warrant caution. Key catalysts include defense contract execution and satellite deployment success, while risks include persistent losses, competitive pressure from SpaceX, and valuation concerns at current P/S of 13.35.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →About Planet Labs
Planet Labs operates Earth-imaging satellites and provides geospatial data products. Its imagery and analytics help governments and businesses monitor changes across the planet.
Read more on PL →
